Catalysts for Shanghai Henlius Biotech Inc
7 tracked
Apr 30, 2026
phase 1 initiation
Shanghai Henlius Biotech Inc — HLX-3901 (Phase I Trial Initiation)
HLX-3901
→
Apr 27, 2026
phase 2 initiation
Shanghai Henlius Biotech Inc — HLX-35 (Phase II Trial Initiation)
HLX-35
→
Apr 25, 2026
phase 2 initiation
Shanghai Henlius Biotech Inc — HLX-43 (Phase II Trial Initiation)
HLX-43
→
Nov 13, 2025
approval
POHERDY (PERTUZUMAB-DPZB) — FDA approval
pertuzumab biosimilar
→
Oct 29, 2025
approval
BILPREVDA (DENOSUMAB-NXXP) — FDA approval
BILPREVDA
→
Aug 29, 2025
approval
BILPREVDA (DENOSUMAB-NXXP) — FDA approval
BILPREVDA
→
Mar 5, 2025
recall
Turbare Manufacturing recall (Cls II)
Shanghai Henlius Biotech Inc
→